This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Billick, E.
Right arrow Articles by Kuhmann, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Billick, E.
Right arrow Articles by Kuhmann, S. E.

 Previous Article  |  Next Article 

Journal of Virology, April 2004, p. 4134-4144, Vol. 78, No. 8
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.8.4134-4144.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

The Differential Sensitivity of Human and Rhesus Macaque CCR5 to Small-Molecule Inhibitors of Human Immunodeficiency Virus Type 1 Entry Is Explained by a Single Amino Acid Difference and Suggests a Mechanism of Action for These Inhibitors

Erika Billick,1,{dagger} Christoph Seibert,2,{dagger} Pavel Pugach,1 Tom Ketas,1 Alexandra Trkola,3 Michael J. Endres,4,{ddagger} Nicholas J. Murgolo,4 Elizabeth Coates,4 Gregory R. Reyes,4 Bahige M. Baroudy,4 Thomas P. Sakmar,2 John P. Moore,1* and Shawn E. Kuhmann1

Department of Microbiology and Immunology, Weill Medical College of Cornell University,1 Laboratory of Molecular Biology and Biochemistry, Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10021,2 Division of Infectious Diseases, Department of Medicine, University Hospital Zurich, 8091 Zurich, Switzerland,3 Schering-Plough Research Institute, Kenilworth, New Jersey 070334

Received 23 July 2003/ Accepted 14 January 2004

AD101 and SCH-C are two chemically related small molecules that inhibit the entry of human immunodeficiency virus type 1 (HIV-1) via human CCR5. AD101 also inhibits HIV-1 entry via rhesus macaque CCR5, but SCH-C does not. Among the eight residues that differ between the human and macaque versions of the coreceptor, only one, methionine-198, accounts for the insensitivity of macaque CCR5 to inhibition by SCH-C. Thus, the macaque coreceptor engineered to contain the natural human CCR5 residue (isoleucine) at position 198 is sensitive to HIV-1 entry inhibition by SCH-C, whereas a human CCR5 mutant containing the corresponding macaque residue (methionine) is resistant. Position 198 is in CCR5 transmembrane (TM) helix 5 and is not located within the previously defined binding site for AD101 and SCH-C, which involves residues in TM helices 1, 2, 3, and 7. SCH-C binds to human CCR5 whether residue 198 is isoleucine or methionine, and it also binds to macaque CCR5. However, the binding of a conformation-dependent monoclonal antibody to human CCR5 is inhibited by SCH-C only when residue 198 is isoleucine. These observations, taken together, suggest that the antiviral effects of SCH-C and AD101 involve stabilization, or induction, of a CCR5 conformation that is not compatible with HIV-1 infection. However, SCH-C is unable to exert this effect on CCR5 conformation when residue 198 is methionine. The region of CCR5 near residue 198 has, therefore, an important influence on the conformational state of this receptor.

* Corresponding author. Mailing address: Joan and Sanford I. Weill Medical College of Cornell University, Department of Microbiology and Immunology, 1300 York Ave., W-805, New York, NY 10021. Phone: (212) 746-4462. Fax: (212) 746-8340. E-mail: jpm2003{at}med.cornell.edu.

{dagger} E.B. and C.S. contributed equally to this work.

{ddagger} Present address: Medarex, Inc., Bloomsbury, NJ 08804.

Journal of Virology, April 2004, p. 4134-4144, Vol. 78, No. 8
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.8.4134-4144.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nolan, K. M., Del Prete, G. Q., Jordan, A. P. O., Haggarty, B., Romano, J., Leslie, G. J., Hoxie, J. A. (2009). Characterization of a Human Immunodeficiency Virus Type 1 V3 Deletion Mutation That Confers Resistance to CCR5 Inhibitors and the Ability To Use Aplaviroc-Bound Receptor. J. Virol. 83: 3798-3809 [Abstract] [Full Text]  
  • Lobritz, M. A., Marozsan, A. J., Troyer, R. M., Arts, E. J. (2007). Natural Variation in the V3 Crown of Human Immunodeficiency Virus Type 1 Affects Replicative Fitness and Entry Inhibitor Sensitivity. J. Virol. 81: 8258-8269 [Abstract] [Full Text]  
  • Saita, Y., Kodama, E., Orita, M., Kondo, M., Miyazaki, T., Sudo, K., Kajiwara, K., Matsuoka, M., Shimizu, Y. (2006). Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist.. J. Immunol. 177: 3116-3122 [Abstract] [Full Text]  
  • Nishikawa, M., Takashima, K., Nishi, T., Furuta, R. A., Kanzaki, N., Yamamoto, Y., Fujisawa, J.-i. (2005). Analysis of Binding Sites for the New Small-Molecule CCR5 Antagonist TAK-220 on Human CCR5. Antimicrob. Agents Chemother. 49: 4708-4715 [Abstract] [Full Text]  
  • Mkrtchyan, S. R., Markosyan, R. M., Eadon, M. T., Moore, J. P., Melikyan, G. B., Cohen, F. S. (2005). Ternary Complex Formation of Human Immunodeficiency Virus Type 1 Env, CD4, and Chemokine Receptor Captured as an Intermediate of Membrane Fusion. J. Virol. 79: 11161-11169 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»